Neuroscience

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

#Neurodevelopmental disorders #Neuroscience #Phase III trial #Rare disease #UCB

UCB reports positive results for neurodevelopmental disorder

Global biopharmaceutical company UCB has reported positive data for its Phase III GEMZ study which is investigating adjunctive fenfluramine in children and adults with CDKL5 Deficiency Disorder (CDD).   The data were announced at the American Epilepsy Society (AES) meeting, Atlanta, USA.  The results… Read More

#Editor's Choice #News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

MRI of dementia patient
#Alzheimer's #Biomarkers #Duke University #Neurodegenerative disorders #Neuroscience

Study supports hippocampal volume as marker in Alzheimer’s

A new study has revealed that hippocampal volume (HV) may be a reliable and measurable surrogate used to assess clinical benefits in early Alzheimer’s disease.  The study results, published in the scientific journal CNS Drugs, show that shrinkage of the hippocampus… Read More

#Editor's Choice #News

Pills
#Alzheimer's #Clinical trial #Spinogenix

Once-a-day pill could reverse cognitive decline, trial shows 

A new once-a-day pill could reverse cognitive decline in Alzheimer’s patients, a clinical trial has shown.  Tazbentetol, developed by biopharmaceutical company Spinogenix, demonstrated rapid, sustained cognitive improvement in a Phase IIa trial. The randomised, double-blind, placebo-controlled trial enrolled 24 patients in Australia, with Tazbentetol proving to be a safe and effective drug with cognitive… Read More

#News

Stem cells
#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Technical Guide: Introducing the Brain-Chip R1

A new Technical Guide is now available from Emulate entitled ‘Characterization of the Brain-Chip R1: A First-in-Class, Isogenic Model of the Human Neurovascular Unit‘. Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight,… Read More

#News

#Assays #Drug development #Drug discovery #iPSC-derived cells #Neuroscience

Introducing the Brain-Chip R1: A new era for human-relevant BBB & NVU research

Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial-like phenotype Maintains resting-state glia and a tight, stable barrier throughout a four-day experimental window Features a streamlined, 12-day direct-to-chip workflow with no pre-plating or expansion steps, enabling robust and reproducible performance… Read More

#Resources #Technical Notes

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

DDW Highlights: 9 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a trade agreement between the UK and the US promised to support… Read More

#Podcasts

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

This week in Drug Discovery (1 – 5 December) 

News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases.  The… Read More

#News

#Neuroscience

Technical Guide – Introducing the Brain-Chip R1: A New Era for Human-Relevant BBB & NVU Research

Key highlights: Incorporates five iPSC-derived cell types, including proprietary BMECs that exhibit a physiologically relevant brain microvascular endothelial–like phenotype Maintains resting-state glia and a tight, stable barrier throughout a four-day experimental window Features a streamlined, 12-day direct-to-chip workflow with no pre-plating or expansion steps,… Read More

#Guides

#AlzeCure Pharma #Alzheimer's #Clinical trial

AlzeCure receives €2.5 million to advance Alzheimer’s drug 

Pharmaceutical company AlzeCure has received a €2.5 million grant from the European Innovation Council (EIC) to advance the Phase II trial of an Alzheimer’s disease treatment.  AlzeCure will advance the candidate NeuroRestore ACD856 to a Phase II trial, developed to improve patients’ learning and memory function and affect the course of disease… Read More

#Business & Investment #News

Peptide
#AltPep Corporation #Alzheimer's #Neurodegenerative disorders #Peptides

Custom-designed peptide could treat Alzheimer’s 

New findings show a custom-designed peptide has promising potential as a treatment for early Alzheimer’s disease (AD).  The candidate SOBIN-AD, developed by biotechnology company AltPep Corporation, demonstrated potential to improve cognition both before and after the onset of cognitive impairment in pre-clinical trial. SOBIN-AD also reduced Aβ… Read More

#News

Alzheimer's disease drug
#Alzheimer's #Clinical trial #Neurodegenerative disorders

Novel therapeutic could treat neurodegenerative diseases 

A novel therapeutic could improve memory, cognitive function and neuroinflammation in neurodegenerative diseases.  VNA-318, developed by biotechnology company Vandria, was tested in preclinical mouse models of neurodegeneration and cognitive impairment. Data shows the candidate created an immediate improvement in memory, learning and cognitive function, as well… Read More

#News

ALS concept
#ALS #Axoltis Pharma #Financing

Axoltis Pharma raises €18 million to advance ALS drug 

Biotech company Axoltis Pharma has raised €18 million to accelerate the development of an amyotrophic lateral sclerosis (ALS) drug candidate.  The closure of a Series A financing round will enable Axoltis to develop lead candidate NX210x, currently in Phase II clinical trials in patients with ALS.  The financing round… Read More

#Business & Investment #News

#ALS #Antibody drug conjugate (ADC) #Breast cancer #DDW Highlights podcast #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Oncology

DDW Highlights: 2 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, gene therapies provided solutions for complex conditions, most notably in Hunter syndrome… Read More

#Podcasts

Neurons in the brain
#Amyotrophic lateral sclerosis (ALS) #Appointment #Neuroscience #New appointment #NRG Therapeutics

NRG Therapeutics appoints Paul Thompson as CDO

NRG Therapeutics has expanded its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).  In his role at NRG, Thompson will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026.   NRG5051 is an oral,… Read More

#News